ASH 2016 | Re-analysis of RESONATE-2 trial of ibrutinib vs chlorambucil in CLL

Paolo Ghia

Paolo Ghia, MD, PhD of Università Vita-Salute San Raffaele, Milan, Italy, discusses the re-analysis of the RESONATE-2 trial comparing chlorambucil vs ibrutinib as first-line treatment for elderly chronic lymphocytic leukemia (CLL) patients with co-morbidities (NCT01722487). The update shows the data is still consistent with the original results; ibrutinib shows high efficacy and this translates in overall survival (OS). Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.

Share this video